Corcept Therapeutics CEO Joseph K. Belanoff provided guidance on the company's future outlook.
2 reports, 2 independent
Updated Aug 13
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Corcept Therapeutics CEO Joseph K. Belanoff provided guidance on the company's future outlook.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Operational disruptions at a pharmacy vendor are negatively impacting Corcept, affecting the company's outlook and operations.Sub-event
CEO Joseph K. Belanoff guided the future outlook for Corcept Therapeutics.1 source
Keep exploring
The entities involved
-
Corcept Therapeutics
American pharmaceutical company
-
Joseph K. Belanoff
researcher
Nothing else this week.
Related events
Coverage
Newest first; wire copies grouped- StockStoryCORT Q2 Deep Dive: Product Supply Constraints and Pipeline Progress Reshape Outlook Biopharma company Corcept Therapeutics (NASDAQ:CORT) missed Wall Street’s revenue expectations in Q2 CY2025, but sa
- Business WireCorcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update Revenue of $194.4 million, compared to $163.8 million in second quarter 2024 Modified 2025 revenue guidan